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ABSTRACT
The monomer of influenza haemagglutinin is synthesized as a single polypeptide precursor that during maturation 
is cleaved by proteases into two active subunits. Other studies have demonstrated that the human Transmembrane 
Protease Serine 2 (TMPRSS2) can cleave the HA of human seasonal influenza viruses. Consequently, we have 
investigated the use of human Transmembrane Protease Serine 2 to produce high titre influenza haemmaggluti-
nin (HA) lentiviral pseudotypes from Group 2 influenza viruses. Such pseudotypes represent powerful and safe 
tools to study viral entry and immune responses. Influenza pseudotype particles are obtained by  co-transfecting 
human embryonic kidney HEK293T/17 cells using plasmids coding for the influenza HA, HIV gag-pol and a 
lentiviral vector incorporating firefly luciferase. However, in order to produce Group 2 pseudotypes, it was nec-
essary to co-transfect a plasmid expressing the TMPRSS2 endoprotease, to achieve the necessary HA cleavage 
for infective particle generation. These lentiviral pseudotypes were shown to transduce HEK293T/17 cells with 
high efficiency. This demonstrates that TMPRSS2 is necessary for the functional activation, in vitro, of both the 
HA of human seasonal influenza and other Group 2 HA influenza strains. Additionally, we show that the Group 
2 influenza pseudotype particles can be used as surrogate antigens in neutralization assays and are efficiently 
neutralized by corresponding influenza virus reference sera. These data demonstrate that the viral pseudotype 
system is a powerful method for serological surveillance of a wide range of influenza viruses.
KEYWORDS: Haemagglutinin, protease cleavage, antibody response, pseudotype serology
INTRODUCTION
Influenza A viruses are disease-causing agents in humans 
and animals, which have a reservoir in wild birds, especially 
Charadriiformes and Anseriformes (Olsen et al, 2006). 
 Influenza A viruses are classified using the antigenic char-
acteristic of the envelope glycoproteins haemagglutinin 
(HA) and neuraminidase (NA). Currently, using antigenic 
characteristics and phylogenetic analysis, 17 different hae-
magglutinin subtypes are recognized and are divided into 
two lineages: Group-1 and Group-2 (Figure 1) (Röhm et al, 
1996; Fouchier et al, 2005; Tong et al, 2012). Of the 17 
haemagglutinin subtypes only two, H1 and H3, cause sea-
sonal epidemics in the human population. However, viruses 
belonging to other subtypes have shown the capacity for 
avian-to-human transmission and their spread needs to be 
monitored in avian and mammalian populations for pan-
demic preparedness (Peiris, 2009). This can be achieved 
using serological and molecular biological diagnostic meth-
ods that permit the identification of haemagglutinin subtypes 
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(Cattoli and Terregino, 2008). The haemagglutinin is the 
major target of antibody response against influenza viruses. 
It is the trimeric envelope glycoprotein necessary for entry 
into susceptible cells. Each HA monomer is produced as a 
single polypeptide precursor, HA0, that during maturation 
is cleaved into two subunits, HA1 and HA2. This process is 
a necessary step to acquire fusion activity and infectivity of 
influenza. When multiple basic amino acid residues (lysine 
and arginine) are situated immediately before the cleavage 
arginine, the haemagglutinin is cleaved by ubiquitously 
expressed subtilisin-like endoproteases, such as furin. This 
determines the virulence and lethality for several avian 
species observed in the high pathogenicity avian influenza 
(HPAI) strains H5 and H7 (Garten and Klenk, 2008). On the 
other hand, cleavage at the single arginine (or lysine) amino 
acid at the HA cleavage site of low pathogenicity avian 
influenza (LPAI) strains, human and mammalian influenza 
viruses is thought to be mediated by tissue-specific pro-
teases. Recently, different human lung proteases belong-
ing to the serine protease family that are able to cleave the 
haemagglutinin of human influenza strains were identified: 
Transmembrane Protease Serine 2 and 4 (TMPRSS2/4) and 
Human Airway Trypsin-like protease (HAT) (Böttcher et al, 
2006; Bertram et al, 2010). To date, the proteases that cleave 
the haemagglutinin of LPAI strains are still unidentified. To 
study the HA cleavage of human seasonal strains (H1 and 
H3) by TMPRSS2, HAT and their avian and mammalian 
homologous proteases, pseudotype lentiviral particles are a 
suitable approach (Bertram et al, 2012). Influenza pseudo-
type particles (pp) represent powerful and safe tools to study 
both the antibody response directed against the influenza 
haemagglutinin and the viral entry mechanism (Garcia and 
Lai, 2011). In the present study, we use a pseudotype gen-
eration system to investigate human TMPRSS2 and its role 
in mediating the conversion of human and LPAI HA0s into 
their active forms, and we show that the pseudotypes pro-
duced can be efficiently used in a virus neutralization assay.
MATERIALS AND METHODS
Haemagglutinin expressing plasmids
The haemagglutinin of A/Udorn/307/1972 (H3N2) and 
of A/chicken/Italy/1082/1999 (H7N1) were cloned in the 
expression plasmid pI.18 using methodology described else-
where (Temperton et al, 2007). The haemagglutinin of A/
duck/Czechoslovakia/1956 (H4N6), A/chicken/Germany/
N49 (H10N7), A/mallard/Astrakhan/263/1982 (H14N5), 
A/shearwater/West Australia/2576/1979 (H15N9) were 
custom synthesised and codon-optimized (Genscript), and 
cloned into the phCMV1 vector (Genlantis) as previously 
reported (Corti et al, 2011).
Reference sera
Reference sheep serum against A/England/427/1988 
(H3N2) was provided by the National Institute for Bio-
logical Standards and Controls (NIBSC, United Kingdom). 
World Organisation for Animal Health (OIE) avian reference 
hyperimmune sera against H3N8, H4N8, H14N5, H10N1 
and H15N9 were produced in specific pathogen-free chick-
ens as described elsewhere (Cattoli et al, 2011). Reference 
avian sera against A/African starling/England/983/1979 
(H7N1), A/chicken/Wales/1306/2007 (H7N2), A/chicken/
England/4054/2006 (H7N3), A/England/268/1996 (H7N7) 
were provided by the Animal Health and Veterinary Labora-
tories Agency (AHVLA).
Cell line
Human embryonic kidney HEK293T/17 cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) with Glu-
tamax and high glucose (Gibco, Invitrogen, UK), supple-
mented with 10% (v/v) fetal bovine serum (Sigma) and 1% 
(v/v) penicillin⁄streptomycin (Fisher Bioreagents).
Pseudotype lentiviral particles production and titration
Lentiviral pseudotyped particles were produced as described 
previously (Temperton et al, 2007; Corti et al, 2011). 
Briefly, the HIV gag-pol plasmid p8.91, the firefly luciferase 
expressing plasmid pCSFLW, the HA expressing plasmid 
and the pCAGGS-TMPRSS2 (Böttcher et al, 2006) were 
 co-transfected into human embryonic kidney HEK293T/17 
cells using Fugene-6 transfection reagent (Roche, UK). 
After 24 hours incubation, 1U of recombinant neuraminidase 
from Clostridium perfringens (Sigma) was added ( Figure 2) 
to facilitate pseudotype exit from the producer cells. Forty-
eight hours post-transfection supernatant was harvested, 
filtered through 0.45 µm filters and stored at -80°C. Pseu-
dotyped particles were also produced in the absence of 
pCAGGS-TMPRSS2 plasmid ('TMPRSS2). Titration of 
the pseudotype particles was performed by transducing 
HEK293T/17 cells (1 × 104 cells/well), with 50  µl of neat 
pseudotype supernatant and subsequent 1:2 serial dilutions.
Group-2
Group-1
Figure 1. Phylogenetic relationship of influenza A haemagglutinin 
subtypes. Evolutionary analysis involving 17 amino acid sequences 
representing HAs from each subtype was conducted in MEGA5 
(Tamura et al, 2011). The evolutionary history was inferred 
using the Neighbor-Joining method, computing the evolutionary 
distances utilizing the Dayhoff matrix-based method. All positions 
with less than 100% site coverage were eliminated. Colours were 
added with FigTree software (http://tree.bio.ed.ac.uk/).
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The 'TMPRSS2 influenza pseudotypes were titrated in 
the absence or presence of TPCK-Trypsin to evaluate the 
effect of endogenous TMPRSS2 expression and to acti-
vate the haemagglutinin to obtain functional pseudotypes. 
TPCK-Trypsin (Sigma) was added to the pseudotypes to 
obtain the final concentration of 50 µg/ml and maintain-
ing constant the TPCK-Trypsin concentration during the 
serial dilution. After 30 min at 37°C, 50 µl of trypsin neu-
tralizing solution (Lonza) were added to each well. After 
48 hrs, luminescence of cell cultures (in relative lumines-
cence units or RLUs) was evaluated by luminometry using 
the Bright-Glo assay system (Promega, UK). Titres were 
expressed in RLU/ml.
Pseudotype particle neutralization assay  
with  reference sera
Reference sera were tested against their respective pseudo-
types by serially diluting 1:2 in culture media (from 1:80 to 
1:5120) in white 96-well flat-bottomed tissue culture plates 
(Nunc) and 50 µl of pseudotype supernatant were added in 
each well, diluted to have a final concentration of 1 × 106 
RLU/well. A ‘cell only’ control and a ‘pseudotype only’ 
(no sera) control were used in each assay. After 1 hr incuba-
tion of sera plus virus at 37°C, 1 × 104 HEK293T/17 cells 
were added to each well and the plates were incubated for a 
further 48 hrs at 37°C. Cell luminescence was measured as 
described above. The results were normalized and expressed 
as the percentage of inhibition of pseudotype virus entry 
(neutralization) using the cell only and pseudotype only 
control RLU values. The half maximal inhibitory concen-
tration (IC
50
) and the 90% inhibitory concentration (IC
90
) 
were calculated with Prism version 6 (GraphPad Software).
RESULTS
The titres of Group-2 influenza pseudotype particles 
expressed in RLU/ml are shown in Figure 3. Through co-
transfection with pCAGGS-TMPRSS2, we successfully 
obtained high-titre viral pseudotype particles harbouring the 
haemagglutinin of a human H3N2 virus (A/Udorn/307/1972), 
A/duck/Czechoslovakia/1956 (H4N6), A/chicken/Germany/
N49 (H10N7), A/mallard/Astrakhan/263/1982 (H14N5), 
A/shearwater/West Australia/2576/1979 (H15N9) and H7 
LPAI virus A/chicken/Italy/1082/1999 (H7N1). Notably, 
H3, H4 and H10 pseudotypes were produced with titres 
above 109 RLU/mL. The pseudotype particle titres obtained 
with TMPRSS2 transfection were compared to the con-
trols: 'TMPRSS2 influenza pseudotypes, 'TMPRSS2 
TPCK-Trypsin activated influenza pseudotypes and pseu-
dotype particles produced without the HA envelope protein 
('envelope). These data indicate that TMPRSS2 activates 
the haemagglutinin not only of human strains, such as A/
Udorn/307/1972 (H3N2), but also the haemagglutinin of 
avian influenza strains (H4, H14, H15, H7 LPAI and H10 
subtypes) in a similar manner to TPCK-Trypsin.
When tested in neutralization assays, the pseudotype par-
ticles were efficiently neutralized by their paired antisera 
(Table 1) using an IC
50
 cut-off dilution of 1:80. The only 
exception was for A/Udorn/307/1972 (H3N2) pseudotype 
that is efficiently neutralized (IC
50
 > 1:5120) by the anti-
A/England/427/1988 (H3N2) sheep serum, but moder-
ately neutralized by the anti-H3N8 sera of avian origin 
(IC
50
 = 1:160-1:320). Different neutralization profiles were 
also observed between the different H7 antisera, with the 
anti-A/chicken/England/4054/2006 (H7N3) exhibiting the 
least potent neutralization activity (IC
50
 = 1:1280-1:2560).
DISCUSSION
We have shown the essential role of TMPRSS2 in the produc-
tion of high-titre Group-2 influenza pseudotype  particles: 
the protease co-expression during virus production mediates 
the haemagglutinin activation of Group-2 human influenza 
and LPAI virus strains and enables functional pseudotype 
particles that have titres comparable to or higher than the 
ones that can be achieved with  TPCK-Trypsin  treatment. 
TMPRSS2 Firefly
Luciferase 
vector
HIV
gag-pol
Haemagglutinin
Exogenous
Neuraminidase +
Haemagglutinin
Firefly Luciferase
HIV gag-pol
Figure 2. Schematic representation of Group-2 influenza 
 pseudotype production. Plasmids encoding HIV gag-pol, the 
 specific HA, TMPRSS2 protease and a Firefly Luciferase 
 encoding lentiviral vector are transfected into HEK293T/17 cells. 
24  hr post-transfection, exogenous neuraminidase is added. 48  hr 
post-transfection, influenza pseudotypes are harvested.
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 subtype (Böttcher et al, 2006) and similarly produced H1 
 pseudotypes have been reported in the literature (Wang et al, 
2008; Corti et al, 2011). In the present study, we show that 
although human TMPRSS2 activates the haemagglutinin of 
different Group-2 subtypes, it is not clear if the difference 
in the titres observed between subtypes are dependent on 
differential HA expression and maturation (glycosylation, 
endoplasmic reticulum and Golgi apparatus trafficking) in 
the HEK293T/17 producer cell line (Ueda et al, 2008) or on 
differential TMPRSS2 recognition and cleavage of the dif-
ferent subtype haemagglutinins. 
The Group-2 influenza haemagglutinins used in this study 
are characterized by the cleavage motif P[E,G][K,V,I]
XX[K,R], with the numbers and physicochemical properties 
of the central aminoacidic residues between the proline and 
the cleavage arginine/lysine variable between subtypes (H3: 
PEKQTR; H4: PEKASR; H14: PGKQAK; H7: PEIPKGR; 
H15: PEKIRTR; H10: PEVVQGR). Recently the structure 
of an H16 subtype haemagglutinin was resolved and it was 
observed that some amino acid residues upstream of the 
Since TMPRSS2 is a protease that is able to cleave human 
influenza haemagglutinins (Böttcher et al, 2006) and TPCK-
Trypsin is able to activate haemagglutinin by proteolitic 
cleavage, we can assume that TMPRSS2 activates the HA 
on pseudotype particles by specific cleavage.
The fact that human TMPRSS2 is able to activate, most 
probably by cleavage, the HAs of different influenza A sub-
types reinforces the concept that haemagglutinin cleavage 
is a conserved process between avian species and humans, 
which was highlighted by the observation that TMPRSS2 
homologous proteins are able to cleave human influenza 
HA (Bertram et al, 2012). However further studies need to 
be performed to determine the function of TMPRSS2 and 
other proteases (e.g., HAT) in haemagglutinin activation 
and cleavage, to examine the cleavage kinetics and to under-
stand the haemagglutinin amino acid residues involved 
in the haemagglutinin-protease interaction. Furthermore, 
it will be interesting to evaluate the ability of TMPRSS2 
to activate LPAI Group-1 influenza haemagglutinin 
 subtypes, since this protease is able to cleave the human H1 
Figure 3. Titres of Group-2 influenza pseudotype particles. Pseudotype transduction titres expressed in Relative Luminescence 
Units per ml (±SEM) are shown. The titres of influenza pseudotype particles produced after transfection of the pCAGGS-TMPRSS2 
 plasmid and the titre of 'TMPRSS2 influenza pseudotype particles, before and after the TPCK-trypsin treatment, are reported.  
'envelope (pseudotype produced without the HA envelope protein) and cell only controls are also included.
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2009; Garcia et al, 2010) and may become the technique 
of choice for HPAI H5 and H7 virus serology. Additionally, 
since the pseudotypes described are replication-defective, 
they offer a safe alternative to wild type virus methods that 
require biosafety level 3 containment, and the detection of 
antibody response is not influenced by the variability of 
blood-based reagents as observed in other assays (i.e. eryth-
rocytes in haemagglutination inhibition) (Rowe et al, 1999). 
Furthermore, the pseudotype neutralization assay appears to 
be more effective than other functional assays to detect the 
antibody response directed against the HA2 haemagglutinin 
stalk (Corti et al, 2011). This is most likely due to the fact 
that, with the absence of neuraminidase on the pseudotype 
particle membrane surface, glycoprotein density is reduced 
and the HA stalk thus becomes more accessible to antibod-
ies. Consequently, pseudotypes could be used to effectively 
study heterosubtypic antibody responses directed against 
the HA stalk region. In this study, with the production of 
Group-2 influenza pseudotypes we present a proof-of-princi-
ple for their use as surrogate antigens in antibody neutraliza-
tion assays. We demonstrate that reference influenza antisera 
efficiently neutralize the matched pseudotypes. Interestingly, 
the human A/Udorn/307/1972 (H3N2) pseudotype is not 
efficiently neutralized by its paired (H3N8) avian antisera 
compared with the sheep H3N2 antisera. This is probably 
due to the fact that H3 avian viruses belong to a different lin-
eage with respect to the human H3 (Zhang et al, 2007). Vari-
ation in the antisera neutralizing titres is also observed when 
the H7 antisera are tested. This is related to the origin of 
the antisera: they were generated against different H7 virus 
strains from the H7 pseudotype strain. This also may reflect 
intra-subtype antigenic differences among H7 strains. Fur-
thermore the different antisera preparations probably have 
different neutralizing titres against their own viral strain. 
Overall, the results presented here reinforce the greater sensi-
tivity of the pseudotype particle neutralization assays described 
previously (Temperton et al, 2007; Garcia et al, 2010). These 
neutralization assays using Group-2  influenza pseudotype par-
ticles, provide additional impetus to optimise, standardise and 
validate this technology as a method to be used for the surveil-
lance of influenza viruses in  animals and humans.
CONCLUSIONS
In the present study we have shown that: 
 s  TMPRSS2 functions in effecting the activation, presum-
ably by cleavage, of Group-2 influenza A virus haemag-
glutinins to produce high-titre influenza pseudotypes.
 s  Influenza pseudotypes can be employed to determine 
which proteases are involved in haemagglutinin activa-
tion of individual subtypes.
 s  Group-2 influenza pseudotype particles are neutralized 
by matched or related reference antisera.
 s  The Group-2 influenza pseudotype particle neutrali-
zation assay could be used as an efficient serologi-
cal  surveillance assay, and for studying the antibody 
response against haemagglutinin elicited by vaccination 
or natural infection.
cleavage site are important in determining the surface acces-
sibility of the cleavage arginine (Lu et al, 2012). A similar 
process could explain the slightly lower titres observed in 
H14 and H15 pseudotypes: H14 haemagglutinin subtypes 
are characterized by a single lysine in their cleavage site 
(PGKQAK) (Kawaoka et al, 1990) and in H15 some amino 
acid residues upstream of the cleavage site (PEKIRTR) dif-
fer from the closely related H7 subtypes (PEIPKGR) (Röhm 
et al, 1996). 
The resolving of the human TMPRSS2 protein structure 
and co-crystallization of TMPRSS2 with human and/or 
avian haemagglutinin could be valuable to delineate the 
amino acid residues involved in the cleavage process. This 
would not only enhance understanding of the haemaggluti-
nin activation mechanism, but importantly may aid develop-
ment of potential protease inhibitors (Zhirnov et al, 2011; 
Böttcher-Friebertshäuser et al, 2012), in a similar manner 
to neuraminidase inhibitor design, for treatment of severe 
influenza virus infections. The panel of Group-2 influenza 
pseudotypes described in this paper, in addition to those pre-
viously produced, could be utilized as tools to test the activ-
ity of these compounds in a pre-clinical screening phase.
The Group-2 influenza pseudotype particles could also 
be used to study the antibody response directed against 
 haemagglutinin. Serological methods, such as haemaggluti-
nation inhibition and microneutralization, are cost-effective 
and widely-used methodologies to monitor the circula-
tion and the prevalence of influenza viruses and are also 
employed in vaccine efficacy studies (Cattoli and Terregino, 
2008). In this report, we have demonstrated that reference 
influenza antisera are able to efficiently neutralize their 
haemagglutinin-paired influenza pseudotype particles. It 
has been previously demonstrated that influenza pseudotype 
particle neutralization assays correlate with other classical 
serological assays (Temperton et al, 2007; Alberini et al, 
Table 1. Half maximal inhibitory concentration (IC
50
) and the 
90% inhibitory concentration (IC
90
) of reference antisera against 
Group-2 influenza pseudotype particles (pp). IC
50 
and IC
90 
were calculated with Graph Pad Prism version 6 and then were 
expressed as assay dilutions.
IC
90
IC
50
H3pp
anti-H3N2 1:1280 >1:5120
anti-H3N8 <1:40 1:160-1:320
H4pp anti-H4N8 1:2560-1:5120 >1:5120
H14pp anti-H14N5 >5120 >1:5120
H7pp
(LPAI)
anti-H7N1 >1:5120 >1:5120
anti-H7N2 1:2560-1:5120 >1:5120
anti-H7N3 1:320-1:640 1:1280-1:2560
anti-H7N7 1:2560-1:5120 >1:5120
H15pp anti-H15N9 >1:5120 >1:5120
H10pp anti-H10N1 1:2560-1:5120 >1:5120
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OIE; World Organisation for Animal Health
Pp; Pseudotype particles
RLU; Relative luminescence unit
TMPRSS2; Transmembrane Protease Serine 2
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